Radioiodine (I-131) for Feline Hyperthyroidism: Cure Rates, Low-Dose Protocols, and Hypothyroidism Risk

Bottom line.

• A prospective cohort study (Lucy et al. 2017, JVIM; n=189 cats with mild-to-moderate hyperthyroidism) demonstrated that low-dose ¹³¹I (2 mCi) achieved a cure rate of >95% while significantly reducing iatrogenic hypothyroidism (1% overt at 6 months) compared to standard-dose 4 mCi (18% overt at 6 months).¹
• Peterson and Rishniw (2021, JVIM) applied an individualized dosing algorithm (T4/T3, thyroid volume, technetium uptake) to 1,400 hyperthyroid cats: 74.8% became euthyroid, 4.1% overtly hypothyroid, 17.1% subclinically hypothyroid, and 4% remained hyperthyroid — with azotemia developing in 71.9% of overtly hypothyroid cats versus 14.2% of euthyroid cats.²
• Radioiodine is the only modality that offers permanent cure with a single outpatient treatment and no ongoing daily medication; it is endorsed as the preferred treatment for most cats in the 2016 AAFP Feline Hyperthyroidism Guidelines.³
• The principal logistical barrier is regulatory: treated cats must be hospitalized in a licensed facility until radiation levels fall to legally permissible discharge thresholds, typically 2–5 days.³
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen and monitoring against current facility protocols and the 2016 AAFP guidelines.

Update context

This update summarizes the current evidence on ¹³¹I cure rates and dosing strategies in hyperthyroid cats, with particular focus on the shift toward individualized and low-dose protocols designed to reduce the historically problematic complication of iatrogenic hypothyroidism.

Managing a hyperthyroid cat and considering radioiodine?

Get an instant cited answer — no signup needed for your first question. Voyage Clinical Desk brings species-specific evidence, monitoring plans, and dosing guidance to the case in front of you.

Try Voyage Clinical Desk

What the evidence shows

Low-dose vs standard-dose: Lucy et al. 2017 (JVIM)

Lucy, Peterson, Randolph et al. (2017) conducted a prospective, nonrandomized cohort study comparing 2 mCi (low-dose) versus 4 mCi (standard-dose) ¹³¹I in 189 client-owned cats with mild-to-moderate hyperthyroidism (serum T4 4.0–13.0 µg/dL).¹ Key outcomes at 6 months:

• Persistent hyperthyroidism: No significant difference between groups (0% standard-dose vs 3.3% low-dose; P=0.51)
• Overt hypothyroidism: 18% standard-dose vs 1% low-dose (P=0.0005)
• Subclinical hypothyroidism (normal T4, high TSH): 46% standard-dose vs 21% low-dose (P=0.004)
• Azotemia: No significant difference in incidence, but standard-dose cats had higher creatinine concentrations and greater percent rises in creatinine

The study concluded that low-dose ¹³¹I is safe and effective for cats with mild-to-moderate hyperthyroidism, producing a cure rate of >95% with significantly reduced hypothyroidism and lower creatinine burden — findings that have driven a substantial shift toward lower-dose protocols in practice.

Individualized dosing algorithm: Peterson and Rishniw 2021 (JVIM)

Peterson and Rishniw (2021) reported outcomes of an individualized ¹³¹I dosing algorithm in a large prospective series of 1,400 hyperthyroid cats.² The algorithm incorporated three disease severity inputs — serum T4 and T3 concentrations, thyroid volume on scintigraphy, and percent uptake of ^99mTc-pertechnetate (TcTU) — to calculate each cat's initial dose; 80% of the composite dose was administered on Day 1, and additional ¹³¹I was given on Day 2 based on measured 24-hour uptake.

Outcomes at 6–12 months:

• Euthyroid: 1,047/1,400 (74.8%)
• Overtly hypothyroid: 57/1,400 (4.1%)
• Subclinically hypothyroid: 240/1,400 (17.1%)
• Persistently hyperthyroid: 56/1,400 (4%)

Critically, azotemia developed in 71.9% of overtly hypothyroid cats, 39.6% of subclinically hypothyroid cats, and 14.2% of euthyroid cats. The median calculated ¹³¹I dose was only 1.9 mCi (range 1.0–10.6 mCi), substantially lower than historical fixed-dose protocols. The authors concluded that the algorithm achieves cure rates comparable to historical rates while markedly reducing the prevalence of both iatrogenic hypothyroidism and post-treatment azotemia.

Why iatrogenic hypothyroidism matters for renal outcomes

The link between post-treatment hypothyroidism and azotemia is mechanistically important. ¹³¹I does not discriminate between hyperplastic/adenomatous tissue and adjacent normal thyroid; standard doses may obliterate the normal tissue, causing hypothyroidism. Hypothyroid cats have reduced GFR, which unmasks pre-existing occult CKD or directly worsens renal perfusion. Both the Lucy et al. and Peterson and Rishniw studies demonstrate that overshoot into hypothyroidism is a modifiable complication with significant impact on renal outcome and, by extension, survival.^1,2

Practical considerations: logistics and candidate selection

The 2016 AAFP guidelines identify radioiodine as the preferred treatment for most hyperthyroid cats because it achieves permanent cure without anesthesia or ongoing medication.³ However, treated cats must be isolated in a licensed facility until radiation activity in urine and body falls below regulatory thresholds (typically 2–5 days in North America). Owners must also observe radiation safety precautions at home after discharge (limited contact, separate litter) for a further 1–2 weeks.

Candidate selection is relatively broad: most cats with confirmed hyperthyroidism and no severe concurrent disease are candidates. Cats with very severe or bilateral thyroid enlargement (highly elevated T4 >15 µg/dL, bilateral uptake) typically require higher ¹³¹I doses and have a higher risk of iatrogenic hypothyroidism at fixed doses.

How this fits clinical practice

The evidence from Lucy et al. (2017) and Peterson and Rishniw (2021) has meaningfully shifted ¹³¹I practice away from fixed standard doses (3–5 mCi) toward individualized or weight-adjusted lower doses, with the goal of euthyroidism rather than thyroid ablation. For general practitioners, the key referral considerations are: (1) pre-referral methimazole trial if concurrent CKD is suspected (see related update); (2) pre-referral client counseling on the isolation requirement; and (3) post-treatment monitoring of T4, TSH, and creatinine at 1, 3, and 6 months. Do not infer specific activity doses from this article; these require scintigraphy and facility-specific protocols.

Voyage Clinical Desk

From clinical question to SOAP draft — cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk

References

1. Lucy JM, Peterson ME, Randolph JF, Scrivani PV, Rishniw M, Davignon DL, Thompson MS, Scarlett JM. 2017. Efficacy of Low-dose (2 millicurie) versus Standard-dose (4 millicurie) Radioiodine Treatment for Cats with Mild-to-Moderate Hyperthyroidism. J Vet Intern Med 31(2):326–334. https://pubmed.ncbi.nlm.nih.gov/28158908/
2. Peterson ME, Rishniw M. 2021. A dosing algorithm for individualized radioiodine treatment of cats with hyperthyroidism. J Vet Intern Med 35(5):2140–2151. https://pubmed.ncbi.nlm.nih.gov/34351027/
3. Carney HC, Ward CR, Bailey SJ, Bruyette D, Dennis S, Ferguson D, Hinc A, Rucinsky AR. 2016. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism. J Feline Med Surg 18(5):400–416. https://pubmed.ncbi.nlm.nih.gov/27143042/

Changelog

• 2026-06-28: First published.